July 2022 Cancer Research UK and Sosei Heptares sign agreement to advance cancer immunotherapy candidate is a novel EP4 antagonist with potential to treat a wide range of cancers in combination with other immunotherapies funder of cancer research, today announce the signing of an agreement to bring Sosei Heptares ’ cancer immunotherapy

Cancer Research UK is working with global biopharma Sosei Heptares on a treatment they hope will bring immunotherapy

September 2022 Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model of immunotherapy

Protein-Coupled Receptors: A Century of Research and Discovery Challenges and opportunities in cancer immunotherapy : a Society for Immunotherapy of Cancer (SITC) strategic vision Structural and Molecular Insights into

GPCRs in Oncology and Immunology The GPCR-Gαs-PKA signaling axis promotes T cell dysfunction and cancer immunotherapy

and Cancer Research UK Announce the Dosing of the First Patient in a Phase I/IIa Trial with Cancer Immunotherapy

Bowel Disease (IBD) Domain Therapeutics and Chime Biologics Form Manufacturing Pact for Antibody Cancer Immunotherapy

GPCRs in Oncology and Immunology A GPCR checkpoint drives CD8+ T cell dysfunction and immunotherapy failure

GPCRs in Immunology and Oncology The GPCR–Gαs–PKA signaling axis promotes T cell dysfunction and cancer immunotherapy

College of Clinical Pharmacology Sosei and Cancer Research UK announce first patient dosed with oral immunotherapy

immune modulator for favorable prognosis in HNSCC through machine learning Prediction of survival and immunotherapy

AI-Driven Drug Discovery Domain Therapeutics CEO Pascal Neuville to Discuss Game-Changing GPCR-Targeting Immunotherapies

and Chime Biologics announce manufacturing agreement  to advance novel anti-CCR8 antibody  for cancer immunotherapy

best-in-class CCR8 antibody candidate, DT-7012, further strengthening its unique portfolio of GPCR-targeting immunotherapies

chemokines and their receptors in several aspects of cancer biology, represents a potential target for immunotherapy

Domain Nominated for Prestigious Prix Galien USA ‘Best Startup’ Award: Pioneering GPCR-Driven Immunotherapies

. · Domain Therapeutics: completed a $42 Million USD Series A round to develop novel immunotherapies